Myriad Ultra ™ Reinforced Tissue Matrix is a sterile bioscaffold composed of ovine (sheep) derived extracellular matrix (ECM) and monofilament polypropylene colored with…
Myriad Ultra ™ Reinforced Tissue Matrix is a sterile bioscaffold composed of ovine (sheep) derived extracellular matrix (ECM) and monofilament polypropylene colored with ([phathalocyaninato(2-)] copper). Myriad™ is intended for applications in plastic and reconstructive surgery or to cover, protect and provide a moist wound environment. The device may be fixed, via sutures, staples or tacks to surround the tissue if desired.
Who Else Makes It
Registered in Shanghai.
Record
Regulatory record for Myriad Ultra™ Reinforced BioScaffold → Permanent (PP) | Listed by | Aroa Biosurgery Ltd, New Zealand |
| FDA product code | FTL |
| Device type | Mesh, Surgical, Polymeric |
| Device class | Class 2 |
| Regulation | 21 CFR 878.3300 |
| Establishment | Contract manufacturer, Complaint-file establishment, Manufacturer |
| 510(k) | K153632 |
| Record published | 2022-11-28 |
| Record revised | 2024-05-29 (version 2) |
Specifications
Specifications | MRI safety | MR Safe |
| Supplied sterile | Yes |
| Single use | Yes |
| Prescription | Prescription only |
| Label carries | lot or batch number, expiry date |
| Sizes | Width 15 cm; length 20 cm |
| Distribution end date | 2024-05-28 |
PMA Approvals
A premarket approval is the full Class III route, granted on clinical evidence rather than on equivalence to an existing device. It is the highest regulatory bar a device of this type can clear.
Source: U.S. FDA establishment registration and device listing records, public domain. Restructured for clarity and searchability. Not affiliated with or endorsed by the FDA. Records are records: nothing here is an offer of sale.